First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine The FDA has granted approval for RYONCIL®, the first therapy using mesenchymal stromal cells (MSCs) to treat children with a rare condition, marking a significant milestone for regenerative medicine.

First FDA-Approved Mesenchymal Stromal Cell Therapy Marks a Major Advancement in Regenerative Medicine #United_States #New_York #Ryoncil #MSC #Osiris_Therapeutics